|Bid||72.00 x 100|
|Ask||73.09 x 200|
|Day's Range||72.83 - 73.32|
|52 Week Range||62.70 - 85.52|
|PE Ratio (TTM)||17.45|
|Earnings Date||Jul 31, 2017 - Aug 4, 2017|
|Dividend & Yield||1.85 (2.54%)|
|1y Target Est||76.11|
NEW YORK, NY / ACCESSWIRE / May 25, 2017 / Since approximately 2009, Negative Pressure Wound Therapy (NWPT) devices have dominated the adjunctive market for wound healing in the United States. The market ...
Like its rivals Cardinal Health (No. 7) and McKesson (No. 73), Amerisource has been buffeted by Wall Street’s concerns about pricing pressure on branded and generic drugs. SEE THE FULL LIST OF THE BARRON’S 500 Amerisource (ABC) “is a key cog within the pharmaceutical industry, as many other supply-chain participants are dependent upon its services for streamlined product distribution and procurement,” notes Vishnu Lekraj, a Morningstar analyst. Sales growth, as it happens, is one of three components in our annual ranking, which spotlights companies that do the best job of boosting revenue and investing for growth.
Jim Cramer discusses the rebound and also mentions the best tech story that no one knows about.